文摘
Renal cell carcinoma (RCC) is often associated with von Hippel-Lindau (VHL) gene mutations, leading to up-regulation of HIFs. From a different point of view, this suggests the possibility that HIFs could be promising targets in anti-cancer therapy. We identified a HIF-1α 278-287 peptide as a candidate of anti-cancer vaccine for HLA-A24+ RCC patients.